Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC lessened its position in Moderna, Inc. (NASDAQ:MRNA) by 83.9% during the fourth quarter, Holdings Channel reports. The fund owned 7,838 shares of the company’s stock after selling 40,925 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Moderna were worth $326,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of MRNA. Principal Financial Group Inc. boosted its position in Moderna by 4.2% during the 3rd quarter. Principal Financial Group Inc. now owns 379,451 shares of the company’s stock worth $25,359,000 after acquiring an additional 15,218 shares during the period. GAMMA Investing LLC grew its position in Moderna by 31.9% in the 4th quarter. GAMMA Investing LLC now owns 3,173 shares of the company’s stock valued at $132,000 after buying an additional 768 shares in the last quarter. Douglas Lane & Associates LLC increased its stake in Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after buying an additional 298,715 shares during the period. Czech National Bank raised its position in shares of Moderna by 6.6% during the 4th quarter. Czech National Bank now owns 73,424 shares of the company’s stock worth $3,053,000 after buying an additional 4,526 shares in the last quarter. Finally, Green Alpha Advisors LLC lifted its stake in shares of Moderna by 54.9% in the 4th quarter. Green Alpha Advisors LLC now owns 16,900 shares of the company’s stock worth $703,000 after acquiring an additional 5,987 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

NASDAQ:MRNA opened at $27.61 on Friday. The stock has a market cap of $10.67 billion, a PE ratio of -2.98 and a beta of 2.23. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock’s 50-day moving average is $29.52 and its two-hundred day moving average is $37.60.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same period in the previous year, the firm posted ($3.07) earnings per share. The firm’s revenue was down 35.3% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Citigroup began coverage on Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 price objective for the company. Leerink Partners lowered their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. The Goldman Sachs Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and cut their price target for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Morgan Stanley lowered their price objective on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 9th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $56.55.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.